Avanir Pharma Places PIPE

Avanir Pharmaceuticals (Nasdaq: AVNR) has completed its previously-announced $40 million sale of common stock and warrants. ProQuest Investments led the PIPE, and was joined by Clarus Ventures, Vivo Ventures and OrbiMed Advisors.



AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced that it has closed the previously reported sale of $40 million of common stock and warrants to a select group of institutional investors led by ProQuest Investments and joined by Clarus Ventures, Vivo Ventures, and OrbiMed Advisors.

“We are pleased that such well respected life-sciences investors understand the potential value of Zenvia